buprenorphine efficacy in methamphetamin dependency

Efficacy of add on buprenorphine vs. placebo on reduction of relapse among people with Met Amphetamine dependency during Matrix program

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090801002266N12

Enrollment

Registered

2020-03-17

Start date

2019-08-23

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine use disorder. Mental and behavioral disorders due to use of other stimulants, including caffeine

Interventions

Intervention 1: Intervention group: buprenorphine In the intervention group, buprenorphine will be started in a sublingual form (made b

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) People 18-60 years old 2)Having the DSM-V criteria for methamphetamine use disorder 3) It is dependent only on methamphetamine 4) No pregnancy and lactation

Exclusion criteria

Exclusion criteria: 1)Any psychiatric disorder that require hospitalization 2) Medical condition that interfere with participating in the study 3)Any side effect that interfere with continuation of buprenorphin

Design outcomes

Primary

Measure	Time frame
Substance use craving. Timepoint: weeks 1-8 and 12,16,20,and 24. Method of measurement: questionair.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Kheirabadi

Esfahan University of Medical Sciences

kheirabadi@bsrc.mui.ac.ir+98 31 3222 2135

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026